Business Description
IGC Pharma Inc
NAICS : 541714
SIC : 2834
ISIN : US45408X3089
Description
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.47 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -12.21 | |||||
| Beneish M-Score | -4.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.1 | |||||
| 3-Year EBITDA Growth Rate | 7.5 | |||||
| 3-Year EPS without NRI Growth Rate | 7.5 | |||||
| 3-Year FCF Growth Rate | 31 | |||||
| 3-Year Book Growth Rate | -45.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.77 | |||||
| 9-Day RSI | 56.39 | |||||
| 14-Day RSI | 51.64 | |||||
| 6-1 Month Momentum % | 66.1 | |||||
| 12-1 Month Momentum % | 24.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.58 | |||||
| Quick Ratio | 0.93 | |||||
| Cash Ratio | 0.51 | |||||
| Days Inventory | 1358.97 | |||||
| Days Sales Outstanding | 32.57 | |||||
| Days Payable | 378.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.7 | |||||
| Shareholder Yield % | -8.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 54.5 | |||||
| Operating Margin % | -728.48 | |||||
| Net Margin % | -966.54 | |||||
| FCF Margin % | -425.18 | |||||
| ROE % | -110.95 | |||||
| ROA % | -92.18 | |||||
| ROIC % | -86.94 | |||||
| ROC (Joel Greenblatt) % | -126.94 | |||||
| ROCE % | -81.5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 19.53 | |||||
| PB Ratio | 4.08 | |||||
| Price-to-Tangible-Book | 5.03 | |||||
| EV-to-EBIT | -3.38 | |||||
| EV-to-EBITDA | -3.61 | |||||
| EV-to-Revenue | 24.62 | |||||
| EV-to-Forward-Revenue | 23.67 | |||||
| EV-to-FCF | -5.8 | |||||
| Price-to-Median-PS-Value | 1.75 | |||||
| Price-to-Net-Current-Asset-Value | 20.1 | |||||
| Earnings Yield (Greenblatt) % | -29.59 | |||||
| FCF Yield % | -16.82 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers